BioCentury
ARTICLE | Targets & Mechanisms

More than one way to stop HCV

August 25, 2011 7:00 AM UTC

A French team led byEpixis S.A. has developed an HCVvaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques.1 Because of the ability to elicit both types of immune responses, the vaccine could have advantages over other HCV vaccines in development that focus only on T cell responses or that elicit neutralizing antibodies that do not attack the multiple genotypes of HCV.

Six companies have HCV vaccines in early stage clinical trials (see "HCV vaccines in clinical development")...